SpringerLink
Log in

Influence of FOXP3 single-nucleotide polymorphism after allogeneic hematopoietic stem cell transplantation

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

The impact of FOXP3 single-nucleotide polymorphisms (SNP) on clinical outcomes after allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains poorly understood. We investigated the relationship between a FOXP3 SNP (rs3761548) and clinical outcomes in 91 patients with hematological malignancies after allo-HSCT. Multivariate analysis showed that risk of severe chronic graft-versus-host disease (cGVHD) was significantly higher in patients with the FOXP3-3279C/A or FOXP3-3279A/A genotype than those with the FOXP3-3279C/C genotype [hazard ratio (HR), 2.69; 95% confidence interval (CI) 1.14–6.31; p = 0.023]. Therefore, FOXP3 at SNP rs3761548 can be a useful marker for predicting the occurrence of severe cGVHD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Data availability

The data that support the findings of the current study are available from the corresponding author, N.H, upon reasonable request.

References

  1. Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol. 2012;12:443–58.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Blazar BR, MacDonald KPA, Hill GR. Immune regulatory cell infusion for graft-versus-host disease prevention and therapy. Blood. 2018;131:2651–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Voermans C, Hazenberg MD. Cellular therapies for graft-versus-host disease: a tale of tissue repair and tolerance. Blood. 2020;136:410–7.

    Article  PubMed  Google Scholar 

  4. Braun LM, Zeiser R. Immunomodulatory therapies for the treatment of graft-versus-host disease. Hemasphere. 2021;5: e581.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003;4:330–6.

    Article  CAS  PubMed  Google Scholar 

  6. Dejaco C, Duftner C, Grubeck-Loebenstein B, Schirmer M. Imbalance of regulatory T cells in human autoimmune diseases. Immunology. 2006;117:289–300.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Oda JM, Hirata BK, Guembarovski RL, Watanabe MA. Genetic polymorphism in FOXP3 gene: imbalance in regulatory T-cell role and development of human diseases. J Genet. 2013;92:163–71.

    Article  CAS  PubMed  Google Scholar 

  8. Ezzeddini R, Somi MH, Taghikhani M, Moaddab SY, Masnadi Shirazi K, Shirmohammadi M, et al. Association of Foxp3 rs3761548 polymorphism with cytokines concentration in gastric adenocarcinoma patients. Cytokine. 2021;138:155351.

    Article  CAS  PubMed  Google Scholar 

  9. Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum—report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2009;15:367–9.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Kalaycio ME, et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood. 2014;123:3664–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Fujiwara S, Hattori N, Matsui T, Nakata A, Sasaki Y, Shimada S, et al. Refined Disease Risk Index for hematological malignancies, including rare disorders, after allogeneic stem cell transplantation. Transplant Proc. 2019;51:3437–43.

    Article  CAS  PubMed  Google Scholar 

  13. Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U, et al. International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium. Biol Blood Marrow Transplant. 2016;22:4–10.

    Article  PubMed  Google Scholar 

  14. Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant. 2015;21:389-401.e1.

    Article  PubMed  Google Scholar 

  15. Schoemans HM, Lee SJ, Ferrara JL, Wolff D, Levine JE, Schultz KR, et al. EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment. Bone Marrow Transplant. 2018;53:1401–15.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Hattori N, Saito B, Sasaki Y, Shimada S, Murai S, Abe M, et al. Status of natural killer cell recovery in day 21 bone marrow after allogeneic hematopoietic stem cell transplantation predicts clinical outcome. Biol Blood Marrow Transplant. 2018;24:1841–7.

    Article  PubMed  Google Scholar 

  17. Suzuki S, Komori M, Hirai M, Ureshino N, Kimura S. Development of a novel, fully-automated genoty** system: principle and applications. Sensors. 2012;12:16614–27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Piao Z, Kim HJ, Choi JY, Hong CR, Lee JW, Kang HJ, et al. Effect of FOXP3 polymorphism on the clinical outcomes after allogeneic hematopoietic stem cell transplantation in pediatric acute leukemia patients. Int Immunopharmacol. 2016;31:132–9.

    Article  CAS  PubMed  Google Scholar 

  19. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8.

    Article  CAS  Google Scholar 

  20. Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG, Strober S, et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med. 2003;9:1144–50.

    Article  CAS  PubMed  Google Scholar 

  21. Jones SC, Murphy GF, Korngold R. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response. Biol Blood Marrow Transplant. 2003;9:243–56.

    Article  PubMed  Google Scholar 

  22. Cao J, Chen C, Zeng L, Li L, Li Z, Xu K. Engineered regulatory T cells prevent graft-versus-host disease while sparing the graft-versus-leukemia effect after bone marrow transplantation. Leuk Res. 2010;34:1374–82.

    Article  CAS  PubMed  Google Scholar 

  23. Zorn E, Kim HT, Lee SJ, Floyd BH, Litsa D, Arumugarajah S, et al. Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood. 2005;106:2903–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Miura Y, Thoburn CJ, Bright EC, Phelps ML, Shin T, Matsui EC, et al. Association of Foxp3 regulatory gene expression with graft-versus-host disease. Blood. 2004;104:2187–93.

    Article  CAS  PubMed  Google Scholar 

  25. Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood. 2002;99:3493–9.

    Article  CAS  PubMed  Google Scholar 

  26. Cohen JL, Trenado A, Vasey D, Klatzmann D, Salomon BL. CD4(+)CD25(+) immunoregulatory T cells: new therapeutics for graft-versus-host disease. J Exp Med. 2002;196:401–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Song P, Wang XW, Li HX, Li K, Liu L, Wei C, et al. Association between FOXP3 polymorphisms and vitiligo in a Han Chinese population. Br J Dermatol. 2013;169:571–8.

    Article  CAS  PubMed  Google Scholar 

  28. **a SL, Ying SJ, Lin QR, Wang XQ, Hong WJ, Lin ZJ, et al. Association of ulcerative colitis with FOXP3 gene polymorphisms and its colonic expression in Chinese patients. Gastroenterol Res Pract. 2019;2019:4052168.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Saxena V, Lakhan R, Iyyathurai J, Bromberg JS. Mechanisms of exTreg induction. Eur J Immunol. 2021;51:1956–67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Jiang W, Zheng L, Xu L, Zhang Y, Liu X, Hu L, et al. Association between FOXP3 gene polymorphisms and risk of differentiated thyroid cancer in Chinese Han population. J Clin Lab Anal. 2017;31: e22104.

    Article  PubMed  Google Scholar 

  31. Jost NH, Abel S, Hutzler M, Sparwasser T, Zimmermann A, Roers A, et al. Regulatory T cells and T-cell-derived IL-10 interfere with effective anti-cytomegalovirus immune response. Immunol Cell Biol. 2014;92:860–71.

    Article  CAS  PubMed  Google Scholar 

  32. Elias S, Rudensky AY. Therapeutic use of regulatory T cells for graft-versus-host disease. Br J Haematol. 2019;187:25–38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Hippen KL, Hefazi M, Larson JH, Blazar BR. Emerging translational strategies and challenges for enhancing regulatory T cell therapy for graft-versus-host disease. Front Immunol. 2022;13:926550.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors thank all patients and clinical staff members who contributed to this study.

Author information

Authors and Affiliations

  1. Division of Hematology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8666, Japan

    Kai Kuroiwa, Hinako Narita, Reiko Okamura, Yuka Uesugi, Yohei Sasaki, Shotaro Shimada, Megumi Watanuki, Shun Fujiwara, Yukiko Kawaguchi, Nana Arai, Kouji Yanagisawa & Norimichi Hattori

  2. Department of Pathology and Laboratory Medicine, Showa University School of Medicine, Tokyo, Japan

    Misuzu Sato & Keiichi Iezumi

Authors
  1. Kai Kuroiwa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Misuzu Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hinako Narita
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Reiko Okamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yuka Uesugi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yohei Sasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Shotaro Shimada
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Megumi Watanuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Shun Fujiwara
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yukiko Kawaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Nana Arai
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Kouji Yanagisawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Keiichi Iezumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Norimichi Hattori
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

NH contributed to the study’s conception and design. Material preparation, data collection, and analysis were performed by MS, KK, and NH. The first draft of the manuscript was written by KK and NH, and all authors commented on previous versions of the manuscript. All authors have read and approved the final manuscript.

Corresponding author

Correspondence to Norimichi Hattori.

Ethics declarations

Conflict of interest

The authors declare no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (XLSX 15 KB): Table S1. Baseline characteristics of patients.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kuroiwa, K., Sato, M., Narita, H. et al. Influence of FOXP3 single-nucleotide polymorphism after allogeneic hematopoietic stem cell transplantation. Int J Hematol 119, 583–591 (2024). https://doi.org/10.1007/s12185-024-03726-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-024-03726-y

Keywords

Search

Navigation